Sanjivani Paranteral Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Sanjivani Paranteral has been growing earnings at an average annual rate of 47.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 24.4% per year. Sanjivani Paranteral's return on equity is 21.7%, and it has net margins of 11.1%.
Belangrijke informatie
47.9%
Groei van de winst
48.3%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 17.5% |
Inkomstengroei | 24.4% |
Rendement op eigen vermogen | 21.7% |
Nettomarge | 11.1% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Sanjivani Paranteral geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 624 | 69 | 53 | 0 |
30 Jun 24 | 583 | 63 | 43 | 0 |
31 Mar 24 | 544 | 62 | 43 | 0 |
31 Dec 23 | 497 | 59 | 49 | 0 |
30 Sep 23 | 438 | 52 | 41 | 0 |
30 Jun 23 | 382 | 43 | 35 | 0 |
31 Mar 23 | 355 | 45 | 33 | 0 |
31 Dec 22 | 326 | 49 | 35 | 0 |
30 Sep 22 | 311 | 57 | 36 | 0 |
30 Jun 22 | 324 | 60 | 31 | 0 |
31 Mar 22 | 306 | 48 | 35 | 0 |
31 Dec 21 | 326 | 48 | 32 | 0 |
30 Sep 21 | 298 | 34 | 30 | 0 |
30 Jun 21 | 283 | 25 | 26 | 0 |
31 Mar 21 | 251 | 14 | 28 | 0 |
31 Dec 20 | 217 | -2 | 27 | 0 |
30 Sep 20 | 199 | -11 | 28 | 0 |
30 Jun 20 | 175 | -17 | 27 | 0 |
31 Mar 20 | 164 | -17 | 28 | 0 |
31 Dec 19 | 179 | -12 | 30 | 0 |
30 Sep 19 | 234 | -13 | 30 | 0 |
30 Jun 19 | 233 | -23 | 28 | 0 |
31 Mar 19 | 251 | -21 | 30 | 0 |
31 Dec 18 | 238 | -216 | 28 | 0 |
30 Sep 18 | 195 | -229 | 29 | 0 |
30 Jun 18 | 187 | -462 | 29 | 0 |
31 Mar 18 | 182 | -531 | 37 | 0 |
31 Dec 17 | 209 | -438 | 35 | 0 |
30 Sep 17 | 266 | -458 | 37 | 0 |
30 Jun 17 | 281 | -233 | 28 | 0 |
31 Mar 17 | 328 | -262 | 33 | 0 |
31 Dec 16 | 322 | -233 | 32 | 0 |
30 Sep 16 | 562 | -190 | 30 | 0 |
30 Jun 16 | 812 | -159 | 27 | 0 |
31 Mar 16 | 1,156 | -146 | 31 | 0 |
31 Dec 15 | 1,474 | -22 | 57 | 0 |
30 Sep 15 | 1,460 | -24 | 58 | 0 |
30 Jun 15 | 1,394 | -31 | 33 | 0 |
31 Mar 15 | 1,330 | -24 | 30 | 0 |
31 Dec 14 | 1,369 | 5 | 73 | 0 |
30 Sep 14 | 1,470 | 17 | 74 | 0 |
30 Jun 14 | 1,596 | 20 | 75 | 0 |
31 Mar 14 | 1,589 | 16 | 77 | 0 |
31 Dec 13 | 1,544 | 34 | 94 | 0 |
Kwaliteitswinsten: 531569 has a high level of non-cash earnings.
Groeiende winstmarge: 531569's current net profit margins (11.1%) are lower than last year (11.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 531569 has become profitable over the past 5 years, growing earnings by 47.9% per year.
Versnelling van de groei: 531569's earnings growth over the past year (32.9%) is below its 5-year average (47.9% per year).
Winst versus industrie: 531569 earnings growth over the past year (32.9%) exceeded the Pharmaceuticals industry 19.1%.
Rendement op eigen vermogen
Hoge ROE: 531569's Return on Equity (21.7%) is considered high.